Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2 At 2023 ASCO Meeting
Portfolio Pulse from Benzinga Newsdesk
Portage Biotech presented updated interim data for its lead iNKT Engager, PORT-2, at the 2023 ASCO Meeting, showing early evidence of single agent activity and meaningful reduction of target lesions. The company plans to expand the Phase 1 trial to evaluate higher dose levels, with data expected by the end of 2023.
June 05, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Portage Biotech's updated interim data for PORT-2 shows promising results, potentially leading to an expanded Phase 1 trial and positive investor sentiment.
The updated interim data for Portage Biotech's lead iNKT Engager, PORT-2, demonstrates early evidence of single agent activity and meaningful reduction of target lesions. This positive news may lead to increased investor confidence in the company's potential for success in the biotech industry. The expansion of the Phase 1 trial to evaluate higher dose levels also indicates progress in the development of the drug, which could positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100